People who do not follow the activities of the US Food and Drug Administration (FDA) closely might be surprised to learn that the agency does not publicly disclose applications for new drugs and therapeutic biologics. The applicants may publicly disclose their applications, such as in press releases or in filings with the Securities and Exchange Commission (SEC), and usually do. The FDA, however, with limited exceptions, does not disclose any information, even about the existence of an application, until—and if—a new medical product is approved. A notable exception is when the FDA asks an advisory committee to discuss an application.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Steinbrook R. Increasing Transparency at the US Food and Drug Administration. JAMA Intern Med. 2019;179(8):1146–1147. doi:10.1001/jamainternmed.2019.1194
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: